drug · protein
pemvidutide
Phase 2updated 5mo agoby $ALT Altimmune, Inc.🔗 ChEMBL
Phase 2community read0 votes
Protein drug with a maximum clinical stage of Phase 2 (across all indications), with 9 investigational indications.
all catalysts(0)
nothing on the calendar yet
Trials studying pemvidutide
- phase3Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH
- phase2RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)
- phase2IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)
- phase2RECLAIM STUDY: A Phase 2 Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight
- phase1Pemvidutide (ALT-801) DDI Study in Healthy Volunteers
News(5)
- Lilly presents early data supporting GLP-1/GIP candidate's potential in depression, alcohol use disorderWith a trillion-dollar market cap and a wildly successful GLP-1 portfolio, Eli Lilly isn’t resting on its laurels. At the Psych Congress 2026, the company presented early-stage data that could supp…biospace · 11d ago
- FDA reviewers criticize Replimune drug; ProMIS climbs on Alzheimer’s dataReplimune shares plummeted 40% on concerns FDA scientists are still skeptical of its melanoma drug. Elsewhere, investors had a muted reaction to a first-of-its-kind study result.biopharma_dive · 2mo ago
- Altimmune rises as GLP-1/glucagon drug curbs heavy drinking in mid-stage studyPemvidutide showed a “highly statistically significant” treatment effect in patients with alcohol use disorder. Altimmune is going up against Eli Lilly and newcomer Baseline Therapeutics, among oth…biospace · 2mo ago
- Updated: Altimmune’s GLP-1-based shot cuts drinking in patients with alcoholismAltimmune said Tuesday that its GLP-1/glucagon agonist reduced drinking in people with moderate-to-severe alcohol use disorder in a mid-stage study. Patients in the Phase 2 RECLAIM trial took a wee…endpoints · 2mo ago
- Altimmune’s next-gen GLP-1 curbs heavy drinking in ‘unequivocal’ ph. 2 alcohol use disorder winAn experimental drug targeting both GLP-1 and glucagon receptors has curbed heavy drinking in a phase 2 trial, providing hope that the ubiquitous weight loss meds can be effectively harnessed again…fiercebiotech · 2mo ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that